FIELD: biotechnology.
SUBSTANCE: what is presented is a recombinant strain Sen-Sdelta(M) of the Sendai virus, used to produce a single-use intranasal vector vaccine against COVID-19, producing the S-protein SARS-CoV-2, including the Sdelta transgene, having the nucleotide sequence SEQ ID NO: 1, containing the gene of the spike S protein of the delta variant of SARS-CoV-2.
EFFECT: invention can be effectively used to produce a single-use intranasal vector vaccine against COVID-1.
1 cl, 8 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
| VIRUS-LIKE PARTICLE VACCINE (VLP) FOR COVID-19 PREVENTION FOR PARENTERAL USE | 2024 |
|
RU2834060C1 |
| POLYPEPTIDE WITH ANTI-SARS-COV-2 ACTIVITY AND PROLONGED CIRCULATION TIME IN BLOOD FLOW | 2023 |
|
RU2822355C1 |
| PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
| METHOD OF CREATING A LIVE VACCINE AGAINST COVID-19 BASED ON THE PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM L3 AND A LIVE VACCINE ENTEROCOCCUS FAECIUM L3-PENTF-COVID-19 | 2020 |
|
RU2745626C1 |
| VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743595C1 |
| PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
| PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
| VACCINE AGAINST INFLUENZA TYPE A, INFLUENZA TYPE B AND COVID-19 | 2021 |
|
RU2751485C1 |
| METHOD FOR CREATING RECOMBINANT ENTEROCOCCUS L3-SARSN1 STRAIN BASED ON BIOLOGICALLY ACTIVE ENTEROCOCCUS FAECIUM L3 STRAIN | 2022 |
|
RU2820058C1 |
